MX2010001711A - Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. - Google Patents
Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.Info
- Publication number
- MX2010001711A MX2010001711A MX2010001711A MX2010001711A MX2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A
- Authority
- MX
- Mexico
- Prior art keywords
- mycophenolate sodium
- extended release
- management
- dosage form
- active agent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229960000951 mycophenolic acid Drugs 0.000 title abstract 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen composiciones farmacéuticas de liberación extendida que comprenden micofenolato sódico como el agente activo, en donde dicha composición exhibe un perfil de liberación característico cuando se somete a un estudio de disolución in vitro, y en donde dicho micofenolato sódico es liberado en una manera sostenida in vivo por una duración prolongada en cantidades tales que sustancialmente alivian o por lo menos reducen las posibilidades de que cause algún efecto secundario gastrointestinal asociado sin que comprometan la biodisponibilidad de dicho agente activo; la presente invención provee también un procedimiento para preparar dichas composiciones de forma de dosificación, y métodos profilácticos y/o terapéuticos de uso de dicha forma de dosificación; las composiciones de la presente invención son seguras, efectivas y bien toleradas, y son útiles para el manejo tal como profilaxis, mejora y/o tratamiento de enfermedades/trastornos indicadas como inmunosupresor, especialmente para el tratamiento o prevención del rechazo de aloinjertos o xenoinjertos de órganos, tejidos o células, por ejemplo, después de trasplante, o el manejo de enfermedades mediadas por el sistema inmune (enfermedades autoinmunes).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1714DE2007 IN2007DE01714A (es) | 2004-09-08 | 2007-08-13 | |
| PCT/IN2008/000505 WO2009022355A1 (en) | 2007-08-13 | 2008-08-11 | Extended release compositions comprising mycophenolate sodium and processes thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001711A true MX2010001711A (es) | 2010-03-11 |
Family
ID=40350431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001711A MX2010001711A (es) | 2007-08-13 | 2008-08-11 | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9642808B2 (es) |
| EP (1) | EP2187872A4 (es) |
| KR (1) | KR20100063059A (es) |
| AR (1) | AR070017A1 (es) |
| AU (1) | AU2008288106B2 (es) |
| BR (1) | BRPI0816231A2 (es) |
| CL (1) | CL2008002380A1 (es) |
| MX (1) | MX2010001711A (es) |
| RU (1) | RU2010109408A (es) |
| WO (1) | WO2009022355A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985994B (zh) * | 2005-12-19 | 2011-01-12 | 康泰乐(北京)医药科技发展有限公司 | 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 |
| PT2049123E (pt) | 2006-08-03 | 2013-03-06 | Horizon Pharma Ag | Tratamento de doença reumatóide com glucocorticóide de libertação retardada |
| EP2488173A1 (en) * | 2009-10-13 | 2012-08-22 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
| EP2576591A2 (en) | 2010-06-07 | 2013-04-10 | Telik, Inc. | Tablet formulation of ezatiostat |
| US8759303B2 (en) | 2010-06-07 | 2014-06-24 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| US8841476B2 (en) | 2010-06-07 | 2014-09-23 | Telik, Inc. | Preparation of crystalline ezatiostat hydrochloride ansolvate form D |
| GB201100786D0 (en) | 2011-01-18 | 2011-03-02 | Ems Sa | Pharmaceutical compositions of immunosuppressants |
| JP2015537029A (ja) | 2012-11-14 | 2015-12-24 | ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 |
| US11633378B2 (en) | 2017-03-13 | 2023-04-25 | Okava Pharmaceuticals, Inc. | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals |
| US10835489B2 (en) | 2018-03-09 | 2020-11-17 | University Of Saskatchewan | Modified release formulations of mycophenolate mofetil |
| CN112730680B (zh) * | 2020-12-24 | 2024-02-13 | 浙江长典药物技术开发有限公司 | 吗替麦考酚酯的溶出曲线测定方法 |
| CN116196286A (zh) * | 2023-02-17 | 2023-06-02 | 卓和药业集团股份有限公司 | 一种麦考酚钠胃漂浮片 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334593A (en) * | 1990-01-13 | 1994-08-02 | Yamasa Shoyu Kabushiki Kaisha | Anxiolytic drugs |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| CN1994295A (zh) * | 2006-01-06 | 2007-07-11 | 华北制药集团新药研究开发有限责任公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
-
2008
- 2008-08-11 US US12/672,180 patent/US9642808B2/en active Active
- 2008-08-11 MX MX2010001711A patent/MX2010001711A/es not_active Application Discontinuation
- 2008-08-11 AU AU2008288106A patent/AU2008288106B2/en not_active Ceased
- 2008-08-11 KR KR1020107005378A patent/KR20100063059A/ko not_active Withdrawn
- 2008-08-11 BR BRPI0816231-0A patent/BRPI0816231A2/pt not_active IP Right Cessation
- 2008-08-11 RU RU2010109408/15A patent/RU2010109408A/ru unknown
- 2008-08-11 EP EP08789927.4A patent/EP2187872A4/en not_active Withdrawn
- 2008-08-11 WO PCT/IN2008/000505 patent/WO2009022355A1/en not_active Ceased
- 2008-08-13 CL CL2008002380A patent/CL2008002380A1/es unknown
- 2008-08-13 AR ARP080103537A patent/AR070017A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR070017A1 (es) | 2010-03-10 |
| CL2008002380A1 (es) | 2009-01-09 |
| EP2187872A4 (en) | 2013-09-18 |
| AU2008288106A1 (en) | 2009-02-19 |
| RU2010109408A (ru) | 2011-09-20 |
| US9642808B2 (en) | 2017-05-09 |
| US20110223249A1 (en) | 2011-09-15 |
| AU2008288106B2 (en) | 2012-03-15 |
| WO2009022355A1 (en) | 2009-02-19 |
| BRPI0816231A2 (pt) | 2015-06-16 |
| KR20100063059A (ko) | 2010-06-10 |
| EP2187872A1 (en) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010001711A (es) | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
| MX348705B (es) | Composiciones farmacéuticas y métodos de administración relacionados. | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| WO2006113864A3 (en) | Oxindole compounds and their uses as therapeutic agents | |
| IL151503A0 (en) | Therapeutic combinations of antihypertensive and antiagiogenic agents | |
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| WO2010078285A3 (en) | Pharmaceutical compositions and methods of treating neurological insults | |
| ATE500817T1 (de) | Schäumbare zusammensetzung, die im wesentlichen frei von pharmazeutisch aktiven inhaltsstoffen ist, zur behandlung der menschlichen haut | |
| MY142067A (en) | Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| AR045957A1 (es) | Composicion farmaceutica y combinacion | |
| WO2007025005A3 (en) | Sustained release formulations of nalbuphine | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| UA106361C2 (ru) | Фармацевтическая композиция для лечения эссенциальной тромбоцитемии | |
| WO2009022842A3 (en) | Pharmaceutical composition for preventing and treating cell proliferative disease comprising mixture of feather of birds and scale of fish as an active ingredient | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| WO2009111681A3 (en) | Gallium compounds and methods of use to treat inflammatory bowel disease | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |